Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q3 2014 · 10-Q
Revenue$1.84M$1.84M−80.6% vs Q3 2013 Net Income-$7.18M-$7.18MN/M vs Q3 2013 EPS Diluted-$0.12-$0.12N/M vs Q3 2013 Operating Income-$8,331,166N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$8,364,069N/M Margins · derivedOperating margin-452.7%−460.8 pt vs Q3 2013
Net margin-390.0%−64.5 pt vs Q3 2013
ended Sep 30, 2014 · filed Nov 10, 2014 · 41 d after period end